• Clinical Trials Available

  Contact the Clinical Trials Team

  For more information about available or upcoming studies, please contact the Clinical Trials team.

  Telephone: (949) 824-3250 or (949) 824-5733
  Email: byanez@uci.edu

  Gammaglobulin Alzheimer’s Partnership Study (GAP)

  This clinical research study is designed to evaluate the effectiveness, safety, and tolerability of an investigational drug for Alzheimer’s, and to determine if this investigational drug may help slow the progression of this disease.

  Patients may be eligible to participate in the GAP Study if they:

  • Are 50 to 89 years old
  • Have been diagnosed with probable mild-to-moderate Alzheimer’s disease
  • Have a study partner (a spouse, child, sibling, or other caregiver) who can be present at every study visit to monitor the participant, and to help him or her complete key study procedures

  If the individual agrees to participate, they will be one of 360 subjects enrolled in the study, which will take place at 36-40 AD treatment sites in the United States. Approximately 10 subjects from this facility will participate in this study. This is a randomized, double-blind, placebo-controlled study. If the patient is found to be eligible for this study, the total period of his/her participation will be approximately 20 months. In this study, the patient will be given either a placebo (an inactive substance) or IGIV infusions intravenously (through a vein in the arm) every two weeks over a 70-week period followed by a 6-week follow-up period without treatment. All participants receive study-related care and monitoring and study-related drugs, at no cost.

  Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity

  Why are we doing this research study?
  Our goal is to determine whether imaging of the brain (through MRI, PET and amyloid imaging) can help predict and/or delay the onset and progression of Alzheimer’s disease.  In addition to neuroimaging, this  study will collect and test blood and cerebral spinal fluid to determine if biomarkers can predict and monitor the disease.  Testing cerebral spinal fluid is the only way to obtain important brain information.

  Who is sponsoring this research study?
  This research study is sponsored by the National Institutes of Health through the Research and Infrastructure “Grand Opportunity” (GO) grant program.

  Where will the research study take place?
  This research study will take place at 50 major university sites across North America.  Researchers are looking for persons who:

  • Are between 55 and 90 years of age
  • Are in good general health but have memory problems or concerns
  • Are fluent in English or Spanish
  • Are willing and able to undergo the test procedures
  • Have a study partner – a friend or relative who can accompany the volunteer to all clinic visits

  Your health will be closely monitored by a team of doctors and nurses, at no cost to you.  Any new information about your physical health will be shared with you and your physician.  You are encouraged to continue seeing your regular doctor.

  If you are interested in participating or have any questions, please call Debba Sultani at (949) 824-5733.

   

Change Text Size